- 16.1% of infants with mild to moderate atopic dermatitis treated with crisaborole ointment 2% experienced treatment-related, treatment-emergent adverse events (TEAEs), according to the phase 4 open-label trial CrisADe CARE 1.
Why this matters
- There are few approved treatment options for infants with atopic dermatitis.
- 64.2% of patients experienced TEAEs.
- 98.9% of TEAEs were rated as mild or moderate.
- TEAEs were considered treatment related for 16.1% of patients.
- The most frequently reported TEAEs were application site pain (3.6%), application site discomfort (2.9%), and erythema (2.9%).
- 30.2% of patients achieved Investigator’s Static Global Assessment (ISGA) of clear/almost clear with ≥2 grade improvement at day 29.
- 137 infants (aged 3 to
- Funding: Pfizer Inc.
- Open-label design.